Virax Biolabs Shareholders Approve Reverse Stock Split at Extraordinary General Meeting

On June 12, 2026, Virax Biolabs Group Limited held a reconvened Extraordinary General Meeting of Shareholders after the initial meeting on June 5 failed to meet a quorum. At the adjourned meeting, shareholders representing 3.65% of outstanding shares were present in person or by proxy, which constituted a quorum according to the Company's Articles of Association. During the meeting, shareholders approved two primary proposals. First, they authorized a share consolidation (reverse stock split) of the Company’s ordinary shares at a ratio ranging from 1-for-10 to 1-for-30. The consolidation will change the par value from $0.001 to a range of $0.01 to $0.30 per share. Second, shareholders approved the adoption of the fourth amended and restated memorandum and articles of association to reflect the revised authorized share capital resulting from the consolidation. Both measures passed with a majority of votes cast, with the share consolidation receiving 517,694 votes 'For' and 202,763 'Against'.